DFTX Definium Therapeutics, Inc.
Company Analysis
Latest News
Definium Therapeutics Rated Overweight, Wells Fargo Cites Mood Disorder Drug Potential
Wells Fargo initiated coverage of Definium Therapeutics (DFTX) on July 27, 2026. Analyst Benjamin Burnett assigned the biotechnology firm an Overweight...
🟢 Definium Therapeutics is trading 4.3% up today amid a broader biotech and psychedelic sector rally
Definium Therapeutics is trading 4.3% up today at $45.03, continuing a strong multi-week run ahead of its next earnings report. • The move is driven by...
🟢 Definium Therapeutics, Inc. is trading 4.37% up
DFTX is trading at $44.67, up 4.37%.
🔴 Definium Therapeutics is trading 4.1% down today on profit-taking after recent Phase 3 trial-driven rally
Definium Therapeutics is trading 4.1% down at $43.80 as shares pull back following a sharp rally driven by positive Phase 3 Emerge trial results for DT120 ODT...
🟢 Definium Therapeutics, Inc. is trading 7.31% up in pre-market
DFTX is trading at $49.00, up 7.31% in pre-market.
🟢 Definium Therapeutics is trading 4.4% up today on technical rebound after sector weakness
Definium Therapeutics is trading 4.4% up at $45.55 as shares rebound from Monday’s technical pullback and broader biotech sector weakness. • The stock is...
🔴 Definium Therapeutics is trading 4.6% down today on technical pullback and broader biotech weakness
Definium Therapeutics is trading 4.6% down at $44.92 as the stock undergoes a technical pullback following its recent rally and broader biotech sector...
🔴 Definium Therapeutics is trading 4.6% down today in a post-rally consolidation
Definium Therapeutics is trading at $46.24 (-4.57%) as the stock undergoes a technical pullback following a sharp +6.91% gain on July 9. • The recent price...
🟢 Definium Therapeutics is trading 4.1% up today following positive Phase 3 trial results and a $700M capital raise
Definium Therapeutics is trading at $47.17 (+4.1%), extending its recent strength after reporting positive clinical data and completing a significant equity...
Definium Therapeutics defeats LSD trade-secret lawsuit, clearing path for drug development
A federal judge in Delaware dismissed a trade-secret lawsuit against psychedelic therapy developer Definium Therapeutics. Clinical-trial provider Signant...
🔴 DFTX extends move to 5.0% down
DFTX is trading at $44.68, down 5.0% versus the comparison close of $47.04 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 Definium Therapeutics, Inc. is trading 4.29% down
DFTX is trading at $45.02, down 4.29%.
🟢 DFTX extends move to 5.2% up
DFTX is trading at $48.98, up 5.2% versus the comparison close of $46.55 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 DFTX is trading 4.2% up today on Oppenheimer upgrade and DT120 trial progress
DFTX is trading 4.2% up at $48.52 following a recent Oppenheimer upgrade to a $60 price target and positive DT120 clinical trial progress. • The move extends...
🔴 DFTX is trading 4.1% down today after closing an upsized $805M equity offering
DFTX is trading at $42.95 (4.1% down) as investors digest the impact of a large, upsized equity raise following its recent clinical rally. • The company...
Definium Therapeutics Secures $758 Million, Advancing Late-Stage Psychiatric Pipeline
Definium Therapeutics, Inc. closed its underwritten public offering of 20,588,236 common shares. The shares were priced at $34.00 per share. The offering was...
🟢 DFTX makes sharp 10.7% jump
DFTX is trading at $46.62, up 10.7% versus the comparison close of $42.13 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 DFTX is trading 6.5% up today after pricing $805M equity offering to fund CNS pipeline
DFTX is trading 6.5% up at $44.88 as investors react to its upsized $805 million equity raise. • The company priced an underwritten public offering of common...
Definium Therapeutics Announces ~$805M Public Offering of Common Stock
Definium Therapeutics, Inc. has entered into an underwriting agreement for a public offering of its common shares, expecting to raise approximately $758...
🟢 DFTX is trading 17% up today on Phase 3 trial success and $700M equity offering
DFTX is trading 17% up at $42.19 as investors react to positive Phase 3 results for its depression drug candidate and a significant capital raise. • The stock...